RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Trial Profile

RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Vanoxerine (Primary)
  • Indications Atrial fibrillation; Atrial flutter
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE SR
  • Sponsors Laguna Pharmaceuticals
  • Most Recent Events

    • 23 Nov 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 23 Nov 2015 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2015 as per ClinicalTrials.gov record.
    • 23 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top